B-cell subsets | Controls | All RA patients | DMARD-naïve patients | p1 | p2 | TNFi-naïve patients | TNFi ongoing | p3 | Baseline TNFi introduction | p4 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | 3 months | ||||||||||
CD19+ | 6.8 (2.5 to 8.7) | 4.4 (3.3 to 6.1) | 4.1 (3.1 to 9.6) | NS | NS | 4.8 (3.6 to 7.4) | 4.4 (3.1 to 6.3) | NS | 5.3 (3.9 to 6.3) | 7.7 (6.7 to 10.6) | ** |
(% lymphocytes) | |||||||||||
CD27+ | 22.0 (18.7 to 34.8) | 25.4 (16.8 to 37.6) | 34.4 (17.6 to 44.4) | NS | NS | 25.2 (17.7 to 36.4) | 30.0 (11.7 to 42.7) | NS | 28.3 (19.6 to 36.2) | 28.4 (19.0 to 39.6) | NS |
(% CD19+) | |||||||||||
CD27+IgD+ | 10.4 (6.2 to 15.5) | 8.0 (4.6 to 13.2) | 8.0 (4.3 to 10.0) | NS | NS | 8.0 (4.9 to 12.9) | 10.5 (4.1 to 15.2) | NS | 9.3 (5.4 to 14.2) | 7.5 (3.4 to 12.7) | NS |
(% CD19+) | |||||||||||
CD27+IgD- | 15.4 (10.2 to 21.7) | 16.6 (11.0 to 25.3) | 22.2 (13.8 to 39.1) | NS | NS | 15.2 (10.7 to 24.4) | 17.3 (9.2 to 28.6) | NS | 15.9 (12.7 to 24.5) | 21.3 (13.2 to 24.8) | NS |
(% CD19+) | |||||||||||
CD27-IgD+ | 73.1 (58.2 to 77.1) | 65.7 (54.2 to 77.1) | 58.5 (45.4 to 74.8) | NS | NS | 68.5 (56.8 to 77.0) | 65.0 (50.9 to 82.1) | NS | 63.5 (54.4 to 76.7) | 62.1 (49.6 to 73.7) | NS |
(% CD19+) | |||||||||||
CD27-IgD- | 2.8 (1.9 to 4.5) | 4.7 (3.0 to 7.2) | 5.8 (3.2 to 9.5) | NS | NS | 4.7 (3.0 to 6.7) | 3.8 (2.9 to 7.5) | NS | 4.7 (3.0 to 6.9) | 6.8 (4.2 to 10.3) | NS |
(% CD19+) |